Waypoint Bio, a NYC-based biotechnology company providing novel cell therapies for solid tumors, raised $14.5M in Seed funding.
The round was led by Hummingbird Ventures with participation from other investors, including Recode Ventures and pre-seed lead Fifty Years.
The company intends to use the funds to further enhance its CAR T-cell therapies with efficacy against the tumor microenvironment, and later, Treg therapies for autoimmune diseases.
Co-founded by CEO Xinchen Wang and CSO David Phizicky, Waypoint Bio is a biotechnology company advancint novel cell therapies for solid tumors using its proprietary spatial pooled screening technology and lab-in-the-loop approach. While the company is currently focused on designing novel, solid tumor cell therapies for cancer, its technology empowers drug discovery applications, including Treg therapies for autoimmune diseases.
The co-founders are joined by a team of 11 researchers, scientists and engineers, and a diverse, expert Scientific Advisory Board, comprised of:
- Melina Claussnitzer, PhD, Broad Institute of Harvard & MIT
- Robbie Majzner, MD, Dana-Farber Cancer Institute
- Yvonne Chen, PhD, UCLA
- Shantanu Singh, PhD, Broad Institute
- Ron Lennox, D.Phil. MBA, Biotech entrepreneur and investor
FinSMEs
28/06/2024